Emerging Severe Mental Illness In Young People: Clinical Staging, Neurobiology, Prediction & Intervention From Vulnerabi
Funder
National Health and Medical Research Council
Funding Amount
$6,229,421.00
Summary
Mental disorders, such as psychotic and severe mood disorders, are the largest cause of disability in Australia. However, there is still little known about illness onset, relapse and progression. We have developed a clinical staging model with transition points from symptomfree to subthreshold status, to threshold disorder to chronic disability. We will investigate neurobiological and psychosocial factors which increase the risk of progression through these stages and use this model as a basis f ....Mental disorders, such as psychotic and severe mood disorders, are the largest cause of disability in Australia. However, there is still little known about illness onset, relapse and progression. We have developed a clinical staging model with transition points from symptomfree to subthreshold status, to threshold disorder to chronic disability. We will investigate neurobiological and psychosocial factors which increase the risk of progression through these stages and use this model as a basis for examining the effectiveness of interventions, for example to prevent, delay or ameliorate onset and relapse, and promote vocational recovery. Thus major clinical and public health benefits and an understanding of factors that contribute to the onset and progression of illness will result.Read moreRead less
The Prevention, Early Detection, & Effective Management Of Neurocognitive Disorders In The Elderly
Funder
National Health and Medical Research Council
Funding Amount
$4,929,014.00
Summary
The unprecedented greying of the world population is posing a major challenge to health care in meeting the needs of older individuals with cognitive disorders such as Alzheimer�s disease. At the same time, drugs are being developed to prevent these disorders, or to treat them effectively. Our proposal is a comprehensive attempt at dealing with the neuropsychiatric aspects of these neurocognitive disorders. Our group is endeavouring to better define the early stages of these disorders, and study ....The unprecedented greying of the world population is posing a major challenge to health care in meeting the needs of older individuals with cognitive disorders such as Alzheimer�s disease. At the same time, drugs are being developed to prevent these disorders, or to treat them effectively. Our proposal is a comprehensive attempt at dealing with the neuropsychiatric aspects of these neurocognitive disorders. Our group is endeavouring to better define the early stages of these disorders, and studying methods of detecting them at an early stage, using the latest neuropsychological and neuroimaging techniques. We wish to investigate new drugs for the prevention of dementia. Much of dementia is not treated early because of lack of training of primary care physicians in identifying dementia, and we are developing methods to deal with this problem. We are also examining the role of cognitive disorders in accidents and suicides in the elderly, and the development of depression. We are determining the role of psychiatric disorders in the care of these patients, and the methods of alleviating the burden of disease. We expect that this research will make a major impact on health policy for these disorders in Australia. We also hope to make our Program the premier centre for training in geriatric neuropsychiatry.Read moreRead less
Prevention, Early Detection And Effective Management Of Neurocognitive Disorders In The Elderly
Funder
National Health and Medical Research Council
Funding Amount
$6,547,975.00
Summary
The Program comprises a number of longitudinal studies of ageing individuals to develop methods of diagnosing dementia before symptoms become prominent. We are also examining factors that increase the risk of developing dementia. We wish to translate this research into early and better diagnosis, and the development of new treatments and strategies for dementia care. We expect that this research will make a major impact on health policy in Australia for cognitive disorders in the elderly.
Regulation Of Gene Expression: Biomolecular Interactions In Cellular Development And Disease
Funder
National Health and Medical Research Council
Funding Amount
$2,998,713.00
Summary
This team consists of three of Australia�s younger researchers Merlin Crossley, Joel Mackay and Jacqui Matthews (as Chief Investigators), who are recognized as authorities in the areas of gene regulation and the structural and functional analysis of proteins. They are joined by Mitchell Weiss, a world authority on blood development and clinical disorders,and Alexis Verger, a molecular and cell biologist recruited from France, both as Principal Investigators. Crossley, Mackay and Matthews have wo ....This team consists of three of Australia�s younger researchers Merlin Crossley, Joel Mackay and Jacqui Matthews (as Chief Investigators), who are recognized as authorities in the areas of gene regulation and the structural and functional analysis of proteins. They are joined by Mitchell Weiss, a world authority on blood development and clinical disorders,and Alexis Verger, a molecular and cell biologist recruited from France, both as Principal Investigators. Crossley, Mackay and Matthews have worked as a team for around six years to date, have published together in high-quality international journals, and have received anumber of accolades for their contributions to Australian science. For example, Crossley has won a number of national awards, including the Gottschalk Medal of the Australian Academy of Science; Mackay was recently awarded the Prime Minister�s Prize for Life Scientist of the Year, and Matthews won the only Charles and Sylvia Viertel Medical Research Fellowship to be awarded in 2003. The members of this team have collaborated extensively on the world stage and Crossley, Mackay and Matthews have also taken leadership roles in the Australian scientific community. Mitchell Weiss has been an important collaborator, exchanging reagents and advice, since he and Crossley trained together as postdocs in Stu Orkin�s lab at Harvard in the early 90s. Most recently Weiss, in collaboration with Mackay, has made important discoveries on a-globin production, which has led to several highly significant publications including a seminal paper in Cell in 2004.The program of research put forward in this proposal centres around understanding the mechanisms through which genes are switched on and off, using blood development as a model system, that is also fundamental to human life. The regulation of gene output is essential both during the development of an organism and throughout the course of its life. Problems with this regulation can result in many different disease states, most notably cancer, which includes the many different types of leukemias. At one level, gene output is controlled by networks of specific proteins known as transcription factors that interact both with each other and with DNA. Currently, however, the details surrounding which complexes regulate which genes and the processes that control the making and breaking up of the complexes are not well understood. Knowledge of how these interactions take place will put us in a position to control the output of chosen genes for therapeutic purposes. We propose to use a combination of cell biological, biochemical, and structural approaches to firstly shed light on these complexes and secondly develop reagents that can be used to manipulate the activity of specific genes.Read moreRead less
This program will investigate the strategies used by pathogenic bacteria to cause human diseases. The research will focus on how bacteria initiate infections, how they invade, cause cell and tissue damage and respond to their human host. It will also examine how the host’s innate immune system interacts with these bacteria. The results will provide new insights into host-pathogen interactions and reveal new targets for the development of novel antibacterial drugs and vaccines.